

#8  
Karmen  
10/22/98

CERTIFICATE OF MAILING  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH  
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE  
ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, D.C. 20231 ON 25 September 1998  
Dara L. Dinner  
AGENT/ATTORNEY FOR APPLICANT  
25 Sept 98  
DATE

Attorney Docket No. P31158

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vere Hodge et al. 25 September 1998  
Serial No.: 08/945,249 Group Art Unit No.: 1614  
Filed: 2 February 1998 Examiner: R. Travers  
For: Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of  
Viral Diseases

TRANSMITTAL LETTER

Transmitted herewith is an Amendment in the above-identified application.

EXTENSION OF TIME PETITION

Applicants hereby petition for an extension of time for response from the date of the Examiner's action as needed, the fee being as follows:

(X) one month extension.....	\$ 110
( ) two months extension.....	\$ 400
( ) three months extension.....	\$ 950
( ) four months extension (not beyond statutory time period).....	\$1510

Charge \$110.00 to Deposit Account No. 19-2570. Two copies of this form are enclosed.


Please charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to Deposit Account No. 19-2570. Also, should the Patent and Trademark Office determine that the fee calculated in the above extension petition is not deemed sufficient to have this response considered as being timely filed, this constitutes a petition for extension of time for the minimum period to effect timely filing, and the Commissioner is authorized to debit any necessary fee to said deposit account.

Respectfully submitted,

Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

SMITHKLINE BEECHAM CORPORATION  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5017  
Facsimile (610) 270-5090  
n:\dld\loa\us\31158\31158ext.doc

10/07/1998 RTSERAYE 00000003 192570  
01 FC:115 110.00 CH



Attorney Docket No. P31158

---

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP96/01706	April 23, 1996	April 24, 1995

---

**TITLE OF INVENTION**

Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases

---

**APPLICANT(S) FOR DO/US**

Richard Anthony Vere Hodge and Raymond F. Schinazi

---

**PRELIMINARY AMENDMENT**

Applicants respectfully request that the following amendments and remarks be made of record prior to examination of the above-cited application.

**IN THE CLAIMS:**

Please cancel claim 2.

Please amend the following claims:

Claim 4 (amended). [A ] The method [, composition, or use] according to Claim 1 [, 2, or 3] wherein the (R)-PCV-TP is in the form of a bioprecursor which is a derivative of (R)- PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

Claim 5 (amended). A compound which is a bioprecursor of (R)-PCV-TP [, for use in the method, use, or composition according to claim 1, 2, 3, or 4].

Please add the following claim:

Claim 8. The composition according to Claim 3 wherein the (R)-PCV-TP is in the form of a bioprecursor which is a derivative of (R)- PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

Claim 9. The compound according to Claim 5 wherein the bioprecursor h is a derivative of (R)- PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

- 2 -

Claim 10. The compound according to Claim 7 which is a PL-ASOR derivative.

Claim 11. The compound according to Claim 7 which is a phospholipid derivative.

Claim 12. The compound according to Claim 7 which is a (R)-MP Bis(POM) derivative.

Claim 13. The compound according to Claim 7 which is a (R)-MP diphenyl ester derivative.

Claim 14. The compound according to Claim 7 which is a dimyristoylglycerol diphosphate derivative.

REMARKS

Claim 2 has been cancelled. Claims 4 and 5 have been amended to correspond more closely to U.S. practice, and Claims 8 to 14 have been added. Support for the newly added claims lie in originally filed claims, and are added to correspond to U.S. practice. No new matter is believed added.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

SmithKline Beecham Corp.  
Corp. Intellectual Property (UW2220)  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
(610) 270-5017 - telephone  
(610) 270-5090 - facsimile  
n:\dld\oa\us\31158pre.doc



San 16/8  
9/3/8  
Harmon  
10/21/98  
Date  
1/24/98

**CERTIFICATE OF MAILING**  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN  
AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF  
PATENTS, WASHINGTON, D.C. 20231, ON 25 September 1998

Agent/Attorney for Applicant

DATE  
25 Sept 98

P31158

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Vere Hodge et al. 25 September 1998  
Serial No.: 08/945,249 Group Art Unit No.: 1614  
Filed: 2 February 1998 Examiner: R. Travers  
For: Use of (R)-Penciclovir Triphosphate For the Manufacture of A  
Medicament For the Treatment of Viral Diseases

Assistant Commissioner of Patents  
Washington, D.C. 20231

**RESPONSE**

Sir:

In response to the Examiner's Action mailed 3 August 1998, having a shortened statutory period of thirty (30) days, please enter the following Remarks and Amendments into the record. Also enclosed herewith is a petition for a one (1) month extension of the shortened statutory period set by the Examiner and authorization to charge the required fee to the indicated deposit account.

**In the Claims:**

Please amend the following claims:

Claim 1 (amended). A method of treatment of:

- i) HIV-1 infections in mammals, including humans; or
- ii) HBV infections in mammals, including humans;

which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A):

RECEIVED  
98 OCT - 7 PM 2:06  
GROUP 180